Modulation of Cerebral Blood Flow Using Iron Chelators

Completed · Early Phase 1

Conditions studied: Stroke, Problem of Aging

In brief

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Key facts

Study ID

NCT01365104

Run by

Brigham and Women's Hospital

People needed

97

Starts

2008-03-01

Expected to finish

2014-12-01

Last updated by the study team

2015-01-28

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy adults between the ages of 18-80 years.

You may not qualify if…

• subjects taking vasoactive medications,
• hypertension,
• pregnant women, smokers,
• COPD,
• asthma,
• diabetes mellitus,
• intracranial or carotid stenosis,
• hepatic disease,
• renal disease,
• bone marrow suppression,
• cardiac disease,
• heart failure,
• iron deficiency,
• history of cancer,
• history of head trauma,
• subarachnoid hemorrhage,
• central nervous system vasculitis,
• multiple sclerosis,
• migraines,
• seizures,
• sickle cell disease or trait,
• cardiac arrhythmia,
• unable to give informed consent, or
• poor transcranial Doppler insonation windows.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.